Shares of Moleculin Biotech surged 12.5% to $8.89 after the Houston-based company said it finished treating all 90 patients in the first phase of its most important clinical trial — a study testing whether its experimental cancer drug can help adults with a deadly form of leukemia that has stopped responding to standard treatments. The news is a procedural checkpoint, not proof the drug works, and the real verdict won't arrive until Q1 2027.
• Dosing Is Done, but the Drug Hasn't Proved Anything Yet
The completed Part A is a randomized, double-blind study of 90 patients comparing two doses of its drug combined with a standard chemotherapy against a placebo arm. The comprehensive analysis will evaluate efficacy and safety across the full population and determine which dose advances into the larger Part B stage.
Earlier blinded interim data showed a 37% composite remission rate in patients who had failed a common frontline drug called venetoclax — encouraging, but still blinded, meaning the company can't yet confirm whether the drug or the placebo drove those results.
• The Cash Situation Is Razor-Thin
In July 2026, Moleculin raised $9.3 million through a public offering of shares and warrants priced at just $0.75 per share — a heavily dilutive deal. The company reported a net loss of $33.6 million over the trailing year with zero revenue**.
It executed a 1-for-20 reverse stock split effective October 20, 2026 , a move typically used to meet exchange listing requirements . Part B will require enrolling an additional 222 patients , implying significant future spending and likely more fundraising rounds that would further dilute existing shareholders.
• The Market It's Chasing Is Big — and Crowded
The relapsed/refractory AML treatment market was valued at roughly $2.8 billion in 2024 and is forecast to reach $6.1 billion by 2034. But FDA-approved targeted therapies are already expanding treatment options for genetically defined patient populations , and a robust pipeline of novel immunotherapies and menin inhibitors is driving competitive intensity. Moleculin's drug would need to carve out share against well-funded rivals.
• A Tiny Valuation Means Massive Upside — or Wipeout
The company's market capitalization sits around $6–10 million , a fraction of what a successful cancer drug would be worth. That extreme smallness cuts both ways: positive Q1 2027 data could send the stock multiples higher, but a disappointing readout — or another dilutive capital raise — could be devastating. With earnings due November 9, investors should brace for fresh details on the cash runway before the pivotal data drops.